Disc Medicine’s Bitopertin Shines, Science Talent Drain Sparks Policy Debate, Vedolizumab Clears UC Without Steroids, Doughnut Model Reveals Critical Links, and more...
Published: October 20, 2026
Duration: 12:19
(0:10): Disc Medicine's Bitopertin Shines in Phase 3 EPP Trial, Paving Way for FDA Submission
(1:57): US Faces Science Talent Drain Amid Policy Shifts, Immigrant Contributions Highlighted
(3:54): Vedolizumab Achieves Corticosteroid-Free Disease Clearance, Reduces UC Complications in Phase 4 VERDICT Trial
(6:27): Breakthrough Study Links Topology to Critical Phenomena Using Doughnut Model
(8:09): Japan's Leading Biobank Surpasses 250,000 Participants, Expands Global Research Access
To subscribe visit https://www.brief.news.
For more updates in your inbox each morning visit www.brief.news.
Image credit: Shoreline Media Group
(1:57): US Faces Science Talent Drain Amid Policy Shifts, Immigrant Contributions Highlighted
(3:54): Vedolizumab Achieves Corticosteroid-Free Disease Clearance, Reduces UC Complications in Phase 4 VERDICT Trial
(6:27): Breakthrough Study Links Topology to Critical Phenomena Using Doughnut Model
(8:09): Japan's Leading Biobank Surpasses 250,000 Participants, Expands Global Research Access
To subscribe visit https://www.brief.news.
For more updates in your inbox each morning visit www.brief.news.
Image credit: Shoreline Media Group